ProCE Banner Activity

CME

A Discussion With Experts on the Evolving Therapeutic Landscape in T-Cell Lymphomas: Focus on EZH1/2 Inhibitors

Multimedia
In this on-demand webcast from a live symposium, Steven M. Horwitz, MD; Pamela B. Allen, MD; and Pierluigi Porcu, MD discuss the rationale, evidence, and strategies for using EZH1/2 inhibitors in patients with peripheral T-cell lymphomas.

Physicians: Maximum of 1.50 AMA PRA Category 1 Credits

Released: June 08, 2022

Expiration: June 07, 2023

No longer available for credit.

Share

Faculty

Steven M. Horwitz

Steven M. Horwitz, MD

Assistant Attending Physician, Lymphoma Service
Department of Medicine
Memorial Sloan-Kettering Cancer Center
New York, New York

Pamela B. Allen

Pamela B. Allen, MD, MSc

Assistant Professor
Department of Hematology/Oncology
Emory University, Winship Cancer Institute
The Emory Clinic
Atlanta, Georgia

Pierluigi Porcu

Pierluigi Porcu, MD

Professor and Director
Division of Hematology Malignancies
Department of Medical Oncology
Thomas Jefferson University
Philadelphia, Pennsylvania

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Daiichi Sankyo, Inc.

Target Audience

This activity is intended for medical oncologists and other healthcare professionals who treat patients with PTCL.

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Describe the mechanism of action of EZH1 and EZH2 inhibitors and the rationale for their use in PTCL
  • Explain emerging clinical trial evidence of the use of anti-EZH1/2 therapies in PTCL
  • Identify adverse events associated with anti-EZH1/2 therapies to implement supportive management strategies
  • Incorporate new data into clinical practice and identify patients eligible for clinical trials

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Program Director Disclosure

Program Director

Steven M. Horwitz, MD

Assistant Attending Physician, Lymphoma Service
Department of Medicine
Memorial Sloan-Kettering Cancer Center
New York, New York

Steven M. Horwitz, MD, has disclosed that he has received consultant/advisor/speaker fees from Acrotech, Affimed, Cimeio Therapeutics, Daiichi Sankyo, Kura Oncology, Kyowa Hakko Kirin, Myeloid Therapeutics, ONO Pharmaceuticals, Secura Bio, Shoreline Biosciences, Takeda, Trillium, Tubulis, Vividion Therapeutics, and Yingli Pharma; and received funds for research support for ADC Therapeutics, Affimed, C4 Therapeutics, Celgene, Crispr Therapeutics, Daiichi Sankyo, Kyowa Hakko Kirin, Millennium/Takeda, Seattle Genetics, and Verastem/Secura Bio.

Faculty Disclosure

Primary Author

Pamela B. Allen, MD, MSc

Assistant Professor
Department of Hematology/Oncology
Emory University, Winship Cancer Institute
The Emory Clinic
Atlanta, Georgia

Pamela B. Allen, MD, has disclosed that she has served on the advisory board for Daiichi Sankyo.

Pierluigi Porcu, MD

Professor and Director
Division of Hematology Malignancies
Department of Medical Oncology
Thomas Jefferson University
Philadelphia, Pennsylvania

Pierluigi Porcu, MD, has disclosed that he has received consultant/advisor/speaker fees from Daiichi Sankyo, Dren Bio, Innate Pharma, MorphoSys, and Viracta; and has served on the Data Safety Monitoring Board for LOXO Oncology.

Staff Disclosure

Staff

Megan Cartwright, PhD

Senior Clinical Editor

Megan Cartwright, PhD has no relevant conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD has no relevant conflicts of interest to report.

Jacqueline L. Olin, MS, Pharm.D., BCPS, FASHP, FCC

Jacqueline L. Olin, MS, PharmD, BCPS, has no relevant conflicts of interest to report.

Brian Purves, PharmD, MBA

Brian Purves, PharmD, MBA has no relevant conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD has no relevant conflicts of interest to report.

Jill A. Sakai,

Contributing Editor

Jill Sakai, PhD has no relevant conflicts of interest to report.

Instructions for Credit

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Additional Information

Participation in this self-study activity should be completed in approximately 1.5 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from June 08, 2022, through June 07, 2023:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.


Goal


The goal of this activity is to improve the knowledge, confidence, and competence of learners in understanding and integrating the latest science and clinical trial data on current and emerging anti-EZH1/2 therapies into treatment plans for patients with PTCL.